India Glycols demerger: key dates and ratios 2026

Why the September 2 investor meet matters

India Glycols is hosting an investor meet in Mumbai on September 2, 2026. The timing is notable because September 2 is also the record date for its approved business demerger, which will determine shareholder eligibility for share allotments in the resulting companies. The company’s demerger is set to split operations into three focused, independently listed plays covering specialty chemicals, spirits and biofuels, and biopharma. For investors, record dates are operationally important because holdings as of that date typically define entitlements in corporate actions like demergers. India Glycols has separately communicated that September 1, 2026 is the demerger’s effective date, while September 2, 2026 is the record date for share allotment.

What the demerger is set to create

Under the approved scheme, India Glycols’ operations will be reorganised into three entities. India Glycols Limited will continue as the remaining business, retaining green chemistry and industrial gases. The potable spirits and biofuels business will be housed in IGL Spirits Limited. The biopharma and polymers business will be housed in Ennature Bio Pharma Limited. After the effective date, the demerged companies are expected to operate as distinct entities.

Effective date vs record date: the key distinction

India Glycols has fixed September 1, 2026 as the effective date for the demerger and September 2, 2026 as the record date. The effective date is the date from which the scheme becomes operational in line with the approvals and filings. The record date is used to determine which shareholders are eligible to receive shares in the resulting companies based on their holdings. In practical terms, investors typically track the record date to ensure their shareholding is reflected in time for eligibility. The company has stated that September 2, 2026 will be used for determining shareholder allotment eligibility.

Share allotment ratios announced for shareholders

The scheme sets out specific entitlement ratios for existing India Glycols shareholders. Eligible shareholders will receive equity shares in both resulting companies based on their holdings as of the record date. The allotment ratios provided are 1 equity share of IGL Spirits Limited for every 1 existing India Glycols share held, and 1 equity share of Ennature Bio Pharma Limited for every 3 existing India Glycols shares held. The article information also specifies that the face value of equity shares referenced is Rs 5 for India Glycols, Ennature Bio Pharma, and IGL Spirits.

What happens to cross-holdings and the remaining business

As part of the scheme, existing equity shares held by India Glycols in the resulting companies will be cancelled once the scheme becomes effective. This step is typically used to simplify the post-demerger capital structure. After the two undertakings are transferred out, the remaining business, assets, and liabilities will continue to vest with India Glycols Limited. The remaining company is described as retaining green chemistry and industrial gases, alongside the broader positioning of the demerger into specialty chemicals, spirits and biofuels, and biopharma.

Regulatory and corporate approvals: what is already on record

India Glycols has stated it received the certified true copy of the National Company Law Tribunal (NCLT) order approving its composite demerger scheme. The NCLT Allahabad Bench sanctioned the scheme on July 17, 2026, and the company said it formally received the document on August 20, 2026. A referenced exchange filing dated August 20, 2026 carried letter number IGL/SE/2026-27/45. The scheme of arrangement involves India Glycols Limited as the demerged company, with Ennature Bio Pharma Limited and IGL Spirits Limited as the resulting companies.

Key dates investors are tracking

The scheme’s appointed date is stated as April 1, 2026. Subsequently, on August 21, 2026, the company fixed September 1, 2026 as the effective date and September 2, 2026 as the record date for share allotment. Separately, an update notes that NSE added dummy Ennature Bio Pharma and IGL Spirits listings to Nifty indices after the India Glycols demerger, dated August 26, 2026. These milestones help investors map the sequence from legal sanction to operational execution.

Listing and index mechanics: what has been indicated

The information provided states that shares of Ennature Bio Pharma Limited and IGL Spirits Limited are expected to be listed on both NSE and BSE. Additionally, the note about NSE adding dummy listings of Ennature Bio Pharma and IGL Spirits to Nifty indices after the demerger reflects standard market infrastructure steps exchanges may take around corporate actions. While dummy listings do not represent tradable price discovery by themselves, they can be used to manage index continuity during such events.

Market impact: what changes for shareholders on the record date

For shareholders, the key operational impact is that the record date of September 2, 2026 will determine who receives shares in the two resulting companies. The entitlement ratios are clearly specified as 1:1 for IGL Spirits and 1:3 for Ennature Bio Pharma, linked to India Glycols shareholding. The effective date of September 1, 2026 establishes when the scheme is considered operational, with September 2 used to take the shareholder snapshot for allotment. The investor meet on September 2, 2026 in Mumbai is therefore aligned with the point at which shareholder eligibility is determined.

Analysis: why this demerger structure is being watched

The structure described splits India Glycols into separate listed vehicles aligned to different business lines: spirits and biofuels in IGL Spirits, biopharma and polymers in Ennature Bio Pharma, and the remaining green chemistry and industrial gases business continuing in India Glycols. For the market, such restructurings can change how investors analyse the company because each entity may be evaluated on its own segment dynamics. The announced allotment ratios give investors a clear framework for how holdings may translate into shares of the new listed entities once the scheme takes effect and allotments are completed. The availability of fixed dates also reduces uncertainty compared with earlier communications that indicated dates would be decided and communicated later.

Conclusion

India Glycols has scheduled an investor meet in Mumbai on September 2, 2026, which also serves as the record date for share allotment under its approved demerger. The effective date is September 1, 2026, and the scheme’s appointed date remains April 1, 2026. Shareholders eligible on the record date are set to receive shares in IGL Spirits (1:1) and Ennature Bio Pharma (1:3), with expected listings on NSE and BSE. The next practical milestones for investors are the record-date snapshot and subsequent allotment and listing processes as communicated by the company and exchanges.